MA49141A - Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau - Google Patents
Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA49141A MA49141A MA049141A MA49141A MA49141A MA 49141 A MA49141 A MA 49141A MA 049141 A MA049141 A MA 049141A MA 49141 A MA49141 A MA 49141A MA 49141 A MA49141 A MA 49141A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolopyridine
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508997P | 2017-05-19 | 2017-05-19 | |
US201862663202P | 2018-04-26 | 2018-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49141A true MA49141A (fr) | 2020-03-25 |
Family
ID=62620966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049141A MA49141A (fr) | 2017-05-19 | 2018-05-18 | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau |
Country Status (11)
Country | Link |
---|---|
US (2) | US11161845B2 (fr) |
EP (1) | EP3624796A1 (fr) |
JP (1) | JP7212956B2 (fr) |
KR (1) | KR102642411B1 (fr) |
CN (1) | CN111065393B (fr) |
AU (1) | AU2018270295B2 (fr) |
CA (1) | CA3063536A1 (fr) |
IL (1) | IL270752B (fr) |
MA (1) | MA49141A (fr) |
MX (2) | MX2019013561A (fr) |
WO (1) | WO2018213810A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA49140A (fr) | 2017-05-19 | 2020-03-25 | Nflection Therapeutics Inc | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |
WO2020106306A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
EP3883554A4 (fr) * | 2018-11-20 | 2022-11-23 | NFlection Therapeutics, Inc. | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
WO2020106303A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |
CA3193191A1 (fr) * | 2020-09-24 | 2022-03-31 | Christopher Powala | Traitement d'un dysfunctionnement cognitif avec des composes pyrrolopyridine-aniline |
CA3205525A1 (fr) * | 2021-01-21 | 2022-07-28 | Stephan D. Parent | Formes cristallines d'un compose de pyrrolopyridine-aniline |
AU2022210443A1 (en) * | 2021-01-21 | 2023-09-07 | Nflection Therapeutics, Inc. | Processes for preparing pyrrolopyridine-aniline compounds |
WO2023096935A1 (fr) * | 2021-11-23 | 2023-06-01 | Nflection Therapeutics, Inc. | Formulations de composés de pyrrolopyridine-aniline |
WO2023178262A1 (fr) | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Traitement à base de mirdamétinib |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (fr) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Formulation a liberation-retard |
ATE272394T1 (de) | 1996-10-31 | 2004-08-15 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter freisetzung |
DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries Ltd | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
US8211875B2 (en) | 2005-02-02 | 2012-07-03 | Nexgenix Pharmaceuticals Inc | Local treatment of neurofibromas |
BRPI0611863B1 (pt) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
GB0601962D0 (en) * | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
ATE531720T1 (de) | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
EP2113500A1 (fr) | 2006-10-31 | 2009-11-04 | Takeda Pharmaceutical Company Limited | Inhibitêur du kinàse MAPK/ERK |
CL2007003444A1 (es) * | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
WO2008148034A1 (fr) | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de mapk/erk kinase |
CA2708176A1 (fr) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines et procedes d'utilisation |
GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
WO2009093008A1 (fr) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
WO2012040636A2 (fr) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase |
WO2014179785A1 (fr) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Répulsifs améliorés contre les abeilles domestiques et leurs utilisations |
CN105384754B (zh) | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
-
2018
- 2018-05-18 US US16/615,086 patent/US11161845B2/en active Active
- 2018-05-18 EP EP18731593.2A patent/EP3624796A1/fr active Pending
- 2018-05-18 KR KR1020197037277A patent/KR102642411B1/ko active IP Right Grant
- 2018-05-18 CA CA3063536A patent/CA3063536A1/fr active Pending
- 2018-05-18 AU AU2018270295A patent/AU2018270295B2/en active Active
- 2018-05-18 MA MA049141A patent/MA49141A/fr unknown
- 2018-05-18 JP JP2020514156A patent/JP7212956B2/ja active Active
- 2018-05-18 MX MX2019013561A patent/MX2019013561A/es unknown
- 2018-05-18 CN CN201880048228.4A patent/CN111065393B/zh active Active
- 2018-05-18 WO PCT/US2018/033547 patent/WO2018213810A1/fr active Application Filing
-
2019
- 2019-11-13 MX MX2022001697A patent/MX2022001697A/es unknown
- 2019-11-18 IL IL270752A patent/IL270752B/en unknown
-
2021
- 2021-08-11 US US17/399,661 patent/US20220033399A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3063536A1 (fr) | 2018-11-22 |
IL270752B (en) | 2022-06-01 |
WO2018213810A1 (fr) | 2018-11-22 |
AU2018270295A1 (en) | 2019-12-05 |
US20220033399A1 (en) | 2022-02-03 |
CN111065393A (zh) | 2020-04-24 |
US20200165243A1 (en) | 2020-05-28 |
JP7212956B2 (ja) | 2023-01-26 |
CN111065393B (zh) | 2023-08-18 |
IL270752A (en) | 2020-01-30 |
AU2018270295B2 (en) | 2022-03-03 |
KR102642411B1 (ko) | 2024-02-28 |
US11161845B2 (en) | 2021-11-02 |
KR20200013239A (ko) | 2020-02-06 |
JP2020520995A (ja) | 2020-07-16 |
MX2019013561A (es) | 2022-02-09 |
EP3624796A1 (fr) | 2020-03-25 |
MX2022001697A (es) | 2022-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
IT201700081018A1 (it) | Trattamento di segnali elettrofisiologici | |
MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
ZA202007055B (en) | Compositions for the treatment of skin conditions | |
DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
ZA202006610B (en) | Compositions for the treatment of skin conditions | |
MA52253A (fr) | Formulation de poudre nasale pour le traitement de l'hypoglycémie | |
MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
MA55144A (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
MA47595A (fr) | Méthodes de traitement d'affections neurodégénératives |